After the publication of the revised edition, therapeutic drugs described in “Future Treatment”
were approved and important evidence for pharmacologic therapy and nonpharmacologic …

Natriuretic peptides, brain (B‐type) natriuretic peptide (BNP) and N‐terminal prohormone of
brain natriuretic peptide (NT‐proBNP) are globally and most often used for the diagnosis of …

The sodium–glucose cotransporter 2 inhibitor empagliflozin reduces the risk of
cardiovascular death or heart failure hospitalization in patients with chronic heart failure, but …

Summary of Key Points In this document, we propose a universal definition of heart failure
(HF) as the following: HF is a clinical syndrome with symptoms and or signs caused by a …

The overwhelming majority of participants in current genetic studies are of European
ancestry. To elucidate disease biology in the East Asian population, we conducted a …

Heart Failure Society (JHFS). The working committee for this project includes members and
collaborators involved in the previous versions of the heart failure guidelines and members …

Background Placement of an interatrial shunt device reduces pulmonary capillary wedge
pressure during exercise in patients with heart failure and preserved or mildly reduced …

Damaged mitochondria are removed by mitophagy. Although Atg32 is essential for
mitophagy in yeast, no Atg32 homologue has been identified in mammalian cells. Here, we …

To elucidate the genetics of coronary artery disease (CAD) in the Japanese population, we
conducted a large-scale genome-wide association study of 168,228 individuals of Japanese …

Objectives: Diastolic dysfunction that determines symptoms and prognosis in patients with
systolic dysfunction causes heart failure even in the absence of systolic dysfunction. Our …